A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium

Key Points

• To compare safety outcomes between nivolumab plus cabozantinib and pembrolizumab plus lenvatinib in the treatment of metastatic renal cell carcinoma.
• Conducted a real-world comparison
• Evaluated toxicity outcomes
• Analyzed treatment efficacy for mRCC
• Nivolumab plus cabozantinib and pembrolizumab plus lenvatinib showed similar effectiveness in treating mRCC.
• Pembrolizumab plus lenvatinib had a higher incidence of severe treatment-related adverse events.